FDA hits Ozempic and Mounjaro counterfeit compounders with warning letters [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
The FDA told the Washington Post that between August 2021 and mid-July 2024, it reviewed 288 reports of patients having bad reactions to compounded semaglutide and 108 such reports for tirzepatide. Some patients required hospitalisation. Although GLP-1 agonist shortages have been improving recently, manufacturers are still struggling to keep up with high demand for these weight-loss drugs. Some patients are turning to compounding pharmacies when they cannot access the branded version of these drugs due to a shortage or other barriers such as cost and insurance coverage. However, the FDA, Eli Lilly (Indianapolis, IN, US), and Novo Nordisk (Bagsvaerd, Denmark) have all expressed quality and safety concerns with compounded weight loss drugs. The organisations found that some compounded versions of semaglutide and tirzepatide were counterfeit, contained too little, too much or no active ingredient at all, or contained the wrong or harmful ingredients. Compounding is a well-established
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health [Yahoo! Finance]Yahoo! Finance
- Should You Invest in the Vanguard Health Care ETF (VHT)? [Yahoo! Finance]Yahoo! Finance
- Ozempic may help manage opioid addiction: study [Fortune]Fortune
- New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitisPR Newswire
- Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's DiseasePR Newswire
LLY
Earnings
- 8/8/24 - Beat
LLY
Sec Filings
- 9/18/24 - Form 3
- 9/17/24 - Form 4
- 9/17/24 - Form 4
- LLY's page on the SEC website